Benitec Biopharma Inc. BNTC
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -45.55M | -41.54M | -44.11M | -41.82M | -37.92M |
| Total Depreciation and Amortization | 481.00K | 475.00K | 462.00K | 423.00K | 396.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 26.41M | 26.26M | 26.41M | 21.41M | 16.66M |
| Change in Net Operating Assets | 2.14M | -4.99M | -1.19M | -2.36M | -2.73M |
| Cash from Operations | -16.52M | -19.79M | -18.43M | -22.35M | -23.59M |
| Capital Expenditure | -105.00K | -26.00K | -17.00K | -18.00K | -18.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -105.00K | -26.00K | -17.00K | -18.00K | -18.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 105.24M | 107.82M | 137.77M | 51.15M | 72.80M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -6.27M | -6.34M | -8.58M | -2.32M | -2.32M |
| Cash from Financing | 98.98M | 101.48M | 129.19M | 48.83M | 70.49M |
| Foreign Exchange rate Adjustments | -125.00K | -233.00K | -187.00K | 230.00K | 49.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 82.23M | 81.43M | 110.56M | 26.69M | 46.93M |